Abivax Ranks 436th in Trading Activity as 320% Volume Surge Fuels Antiviral Pipeline Optimism

On October 6, 2025, Abivax (ABVX) surged 3.28% as trading volume spiked to €0.26 billion, a 320.54% increase from the prior day. The biopharmaceutical company ranked 436th in terms of trading activity among listed equities, reflecting renewed investor interest amid strategic developments in its pipeline. Recent updates highlighted progress in preclinical trials for its antiviral candidate, ABX464, with preliminary data indicating potential for regulatory milestones in 2026. Collaborative efforts with European research institutions to expand clinical trial access also contributed to market optimism.

Analysts noted that the stock's performance aligned with sector-specific catalysts, including renewed focus on antiviral therapeutics post-pandemic. While no immediate earnings reports or partnerships were disclosed, the company’s emphasis on accelerating phase II trials for respiratory virus treatments positioned it favorably in a competitive therapeutic landscape. Institutional activity remained muted, though retail investor participation showed signs of stabilization following a three-month decline in volatility.

To build an accurate back-test for this rotation strategy, we need to confirm a few practical details and set some sensible defaults: 1. Market universe—Should the “top-500” selection be drawn from all U.S. common stocks (≈6,000 names) or a narrower universe such as the Russell 3000 or S&P 1500 constituents? 2. Rebalance rule & trade prices—Do we rank by the previous day’s dollar volume and buy at next day’s open, closing at the following day’s open (1-day holding period)? Or do you prefer close-to-close (buy at today’s close, sell at tomorrow’s close)? 3. Weighting scheme—Equal-weight each of the 500 names (standard for this type of test), or volume-weighted, or something else? 4. Practical constraints—Because this is a 500-stock daily-rotation portfolio, our current single-ticker back-test engine cannot evaluate it directly. I can instead build a custom portfolio back-test outside the one-ticker engine and return the key return & risk metrics, or we can approximate the strategy using a representative ETF universe. Once these points are clarified, I can pull the required volume data, generate the daily selection lists, and run the full portfolio back-test from 2022-01-03 through 2025-10-06.